PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks:
October
- Chardan Gene Therapy Conference (New York, US)
| Date: | Wednesday, October 11 | |||
| Time: | 3:45pm Eastern Time | |||
| Location: | Westin New York Grand Central, Assembly Room |
- Jefferies Gene Editing & Gene Therapy Summit (New York, US)
| Date: | Thursday, October 12 | |||
| Time: | 2:30pm Eastern Time | |||
| Location: | Westin New York Grand Central |
- Key Opinion Leader Lunch: Gene Therapy for Patients with Sanfilippo Syndrome Type A (MPS IIIA) (New York, US)
| Date: | Friday, October 13 | |||
| Time: | 12:00pm – 1:30pm Eastern Time | |||
| Location: | Lotte New York Palace Hotel |
Webcast: http://lifesci.rampard.com/20171013/reg.jsp
November
- Jefferies 2017 London Healthcare Conference (London, UK)
| Date: | Tuesday, November 14 & Wednesday, November 15 | |||
| Time: | TBD | |||
| Location: | Waldorf Hilton |
About Lysogene
Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.
Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475).
For more information: www.lysogene.com.
